Literature DB >> 16359539

PEComa: what do we know so far?

J L Hornick1, C D M Fletcher.   

Abstract

PEComas (tumours showing perivascular epithelioid cell differentiation) are a family of related mesenchymal neoplasms that include angiomyolipoma, lymphangiomyomatosis, clear cell "sugar" tumour of the lung, and a group of rare, morphologically and immunophenotypically similar lesions arising at a variety of visceral and soft tissue sites. These tumours all share a distinctive cell type, the perivascular epithelioid cell or "PEC' (which has no known normal tissue counterpart). PEComas show a marked female predominance and are composed of nests and sheets of usually epithelioid but occasionally spindled cells with clear to granular eosinophilic cytoplasm and a focal association with blood vessel walls. PEComas appear to arise most commonly at visceral (especially gastrointestinal and uterine), retroperitoneal, and abdominopelvic sites, with a subset occurring in somatic soft tissue and skin. Nearly all PEComas show immunoreactivity for both melanocytic (HMB-45 and/or melan-A) and smooth muscle (actin and/or desmin) markers. A subset of PEComas behave in a malignant fashion. This review examines the members of the PEComa family, with an emphasis on lesions arising outside of the kidney, lung and liver, and discusses preliminary evidence for pathological features that might predict malignant behaviour.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16359539     DOI: 10.1111/j.1365-2559.2005.02316.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  109 in total

1.  Abrikosoff's Tumor and the Hepatobiliary System: A Curiosa Revisited.

Authors:  John G Brain; Alastair D Burt
Journal:  Gastroenterol Hepatol (N Y)       Date:  2010-05

2.  A case of pararenal PEComa with extensive bone metaplasia.

Authors:  Carmen L Menéndez; Rodrigo Gil Ugarteburu; Jesús M Capilla Ampudia; Gabriela Corte Torres; Eduardo Fuente; Mario Argüelles
Journal:  Virchows Arch       Date:  2008-03       Impact factor: 4.064

3.  Perivascular epithelioid cell tumour of the liver.

Authors:  Unne Stenram
Journal:  World J Gastroenterol       Date:  2008-05-21       Impact factor: 5.742

Review 4.  Pancreatic perivascular epithelioid cell tumor: A case report with clinicopathological features and a literature review.

Authors:  Hui Jiang; Na Ta; Xiao-Yi Huang; Ming-Hua Zhang; Jing-Jing Xu; Kai-Lian Zheng; Gang Jin; Jian-Ming Zheng
Journal:  World J Gastroenterol       Date:  2016-04-07       Impact factor: 5.742

Review 5.  Diffuse Cystic Lung Disease. Part I.

Authors:  Nishant Gupta; Robert Vassallo; Kathryn A Wikenheiser-Brokamp; Francis X McCormack
Journal:  Am J Respir Crit Care Med       Date:  2015-06-15       Impact factor: 21.405

Review 6.  Perivascular epithelioid tumours (PEComas) of the gynaecological tract.

Authors:  Niamh Conlon; Robert A Soslow; Rajmohan Murali
Journal:  J Clin Pathol       Date:  2015-03-06       Impact factor: 3.411

7.  Growth pattern change of a benign clear cell 'sugar' tumor of the lung: Serial imaging surveillance over seven years.

Authors:  Eung Koo Yeon; Jung Im Kim; Kyu Yeoun Won; Han Na Lee
Journal:  Oncol Lett       Date:  2018-03-30       Impact factor: 2.967

8.  Perivascular epithelioid cell tumor of the liver coexisting with a gastrointestinal stromal tumor.

Authors:  Carlos Eduardo Paiva; Francisco Alves Moraes Neto; Abbas Agaimy; Maria Aparecida Custodio Domingues; Silvia Regina Rogatto
Journal:  World J Gastroenterol       Date:  2008-02-07       Impact factor: 5.742

9.  PEComa of the colon resistant to sirolimus but responsive to doxorubicin/ifosfamide.

Authors:  Wolfgang Scheppach; Nikolaus Reissmann; Thomas Sprinz; Ekkehard Schippers; Bjoern Schoettker; Justus G Mueller
Journal:  World J Gastroenterol       Date:  2013-03-14       Impact factor: 5.742

10.  Perivascular epithelioid cell tumour (PEComa) of the inferior vena cava presenting as an adrenal mass.

Authors:  Santosh Kumar; Anupam Lal; Naveen Acharya; Varun Sharma
Journal:  Cancer Imaging       Date:  2010-03-16       Impact factor: 3.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.